News
Zacks.com on MSN7h
SMMT Stock Gains on Rumored Licensing Talks With AstraZenecaSummit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback